Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.

Autor:	Ramamurthy C; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Wheeler KM; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Trecarten S; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Hassouneh Z; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Ji N; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Lee Y; Department of Urology and Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA., Svatek RS; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA., Mukherjee N; Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA.
Jazyk:	angličtina
Zdroj:	Journal of cancer immunology [J Cancer Immunol (Wilmington)] 2024; Vol. 6 (1), pp. 29-39.
DOI:	10.33696/cancerimmunol.6.081
Abstrakt:	Checkpoint inhibitors offer promise in treating muscle-invasive and metastatic bladder cancer, but the optimal timing of their administration-neoadjuvant or adjuvant-remains unclear. To determine the efficacy of combining checkpoint inhibition with standard cisplatin-based chemotherapy, we conducted a phase II trial of neoadjuvant anti-PD-1 (αPD-1) and anti-CTLA-4 (αCTLA-4), in combination with cisplatin-gemcitabine, for patients with muscle-invasive bladder cancer prior to radical cystectomy. In addition, a novel murine model of spontaneous metastatic bladder cancer was used to compare the efficacy of neoadjuvant versus adjuvant anti-PD-L1 (αPD-L1) treatment. The clinical trial was closed prematurely due to the industry's withdrawal of drug provision. Adverse events were observed in all patients; however, serious adverse events were not observed in any patient. A complete pathologic response was observed in 50% of the 4 patients enrolled. Response to treatment was significantly associated with elevated urinary T cells including CD8 + and IFNγ + CD4 + T cells, suggesting potential reinforcement of immune responses by neoadjuvant αPD-1 and αCTLA-4 against bladder tumor cells. These findings suggest that combining chemotherapy and immunotherapy in the neoadjuvant setting could be safe. However, the complete response rate of this four-drug regimen was modest and emphasizes the need for randomized controlled trials to properly assess immunotherapy efficacy in the neoadjuvant setting. In corresponding murine studies, the MB49-met model consistently displayed widespread metastasis, including tumor growth in the lungs, liver, and bowel mesentery, within 20 days of subcutaneous transplantation. Mice receiving surgery plus neoadjuvant αPD-L1 or adjuvant αPD-L1 exhibited improved survival compared to those receiving only αPD-L1. However, no significant difference in survival was observed between the neoadjuvant and adjuvant αPD-L1 cohorts. Furthermore, the timing of neoadjuvant therapy administration (early vs. late) did not significantly impact survival. This study highlights the potential of perioperative immunotherapy in the treatment of locally advanced and metastatic bladder cancer. Competing Interests: Conflict of Interest The authors have declared that no conflict of interest exists.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu